Nectar Lifesciences Intrinsic Value
NECLIFE Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹28.55 | ₹25.70 - ₹31.41 | +150.0% | Book Value/Share: ₹434.55, P/B: 2.0x |
| Simple DCF (5Y) | dcf | ₹28.55 | ₹22.84 - ₹34.26 | +150.0% | CF Growth: 15.0%, Discount: 15% |
Want to compare with current market value? Check NECLIFE share price latest .
Valuation Comparison Chart
NECLIFE Intrinsic Value Analysis
What is the intrinsic value of NECLIFE?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Nectar Lifesciences (NECLIFE) is ₹28.55 (median value). With the current market price of ₹11.42, this represents a +150.0% variance from our estimated fair value.
The valuation range spans from ₹28.55 to ₹28.55, indicating ₹28.55 - ₹28.55.
Is NECLIFE undervalued or overvalued?
Based on our multi-method analysis, Nectar Lifesciences (NECLIFE) appears to be trading below calculated value by approximately 150.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 17.69 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -73.6% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
Related Pages for Nectar Lifesciences
Additional stock information and data for NECLIFE
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹169 Cr | ₹148 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹225 Cr | ₹217 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹134 Cr | ₹134 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹95 Cr | ₹95 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹21 Cr | ₹7 Cr | Positive Free Cash Flow | 7/10 |